Ecolab (ECL)
(Delayed Data from NYSE)
$243.17 USD
+0.90 (0.37%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $243.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$243.17 USD
+0.90 (0.37%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $243.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Zacks News
Suzano (SUZ) to Buy 2 Mills From Pactiv Evergreen for $110M
by Zacks Equity Research
Suzano (SUZ) signs an agreement with Pactiv Evergreen to acquire two of its US industrial facilities.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PHO
Should You Invest in the Invesco Water Resources ETF (PHO)?
by Zacks Equity Research
Sector ETF report for PHO
Barrick (GOLD) Announces Strategic Plans for Loulo-Gounkoto
by Zacks Equity Research
Barrick (GOLD) emphasizes the importance of sustaining the Loulo-Gounkoto gold mining complex, with a significant economic contribution to Mali.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
by Zacks Equity Research
Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.
Royal Gold (RGLD) Issues Stream Segment Sales Update for Q2
by Zacks Equity Research
Royal Gold (RGLD) sells 52,600 gold equivalent ounces in the June-end quarter of 2024.
DuPont (DD) Tyvek Richmond Facility Gets ISCC+ Certification
by Zacks Equity Research
DuPont's (DD) global integration of ISCC PLUS certification into Tyvek production coincides with the company's commitment to empowering clients on their road to net zero emissions.
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Here's Why You Should Add H.B. Fuller (FUL) to Your Portfolio
by Zacks Equity Research
H.B. Fuller (FUL) presents a substantial investment opportunity with robust earnings outperformance and promising growth prospects.
ArcelorMittal (MT)-Partners Begin Carbon Capture Trial in Ghent
by Zacks Equity Research
ArcelorMittal (MT), MHI and D-CRBN are trialing plasma technology at Gent to convert CO2 into carbon monoxide for steel and chemical production, aiming to reduce emissions.
BASF (BASFY) Expands Sodium Methylate Capacity in South America
by Zacks Equity Research
This capacity increase is another step in BASF's (BASFY) business expansion for sodium methylate in South America, demonstrating the company's commitment to its customers and the South American biodiesel market.
Yara (YARIY) and Scatec Ink Renewable Ammonia Offtake Deal
by Zacks Equity Research
This project will bolster Yara's (YARIY) renewable ammonia sourcing portfolio and allow it to reliably serve its customers across several markets.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Hawkins (HWKN) Strengthens Water Treatment With Wofford Buy
by Zacks Equity Research
Hawkins (HWKN) acquires Wofford Water Service, strengthening its presence in the southern U.S. and expanding its Water Treatment business in Mississippi.
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Sandstorm Gold (SAND) Posts Y/Y Preliminary Q2 Revenue Decline
by Zacks Equity Research
Sandstorm Gold's (SAND) preliminary revenues fall 16.9% year over year, while the cash operating margin improves 17.1% in the second quarter.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Arkema (ARKAY) Gets ISCC+ for Powder Coating Resins Facility
by Zacks Equity Research
The facility of Arkema (ARKAY) includes a polyester resin production line and a cutting-edge R&D laboratory dedicated to increasing the sustainability and performance of powder coating materials
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board
by Zacks Equity Research
Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
by Zacks Equity Research
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
by Zacks Equity Research
Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.